A Phase 1/2 Study of Durvalumab(MEDI4736) and tremelimumab in Chinese Patients with Advanced Malignancies

Trial Identifier: D419AC00006
Sponsor: AstraZeneca
NCTID:: NCT02978482
Start Date: December 2016
Primary Completion Date: January 2018
Study Completion Date: November 2020
Condition: Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version
Chinese Translation

Trial Locations

Country Location
China Changchun, China, 130012
China Changchun, China, 130000
China Changchun, China, 130021
China Chengdu, China, 610041
China Haikou, China, 570311
China Hangzhou, China, 310022
China Hangzhou, China, 310016
China Harbin, China, 150081
China Hefei, China, 230031
China nanchang, China, 330029
China Shanghai, China, 200032
China Shenyang, China, 110016
China Urumchi, China, 830054
China Wuhan, China, 430079
China Wuhan, China, 430022
China Xiamen, China, 361003
China Zhanjiang, China, 524001
China Zhengzhou, China, 450008